[Lung Cancer Screening - Risk Stratification : Who Should Undergo Screening?]

Overview

Journal Radiologe

Specialty Radiology

Date 2016 Aug 7

PMID 27495786

Authors

L Beer

H Prosch

Affiliations

Soon will be listed here.

Abstract

Lung cancer is one of the leading causes of deaths in Europa and the USA. In approximately 75 % of lung cancer patients, bronchogenic carcinoma is detected at an advanced tumor stage; therefore, therapeutic options which aim at curing the disease in these patients are limited and treatment is mostly palliative. A relatively good prognosis is reserved for the minority of patients where the tumor is detected at an early stage and treatment is potentially curative. For this reason, early diagnosis of lung cancer could save lives. Retrospective analyses of the US national lung screening trial (NLST) showed that especially high-risk populations (e. g. higher age, positive smoking history, overweight and a positive family history for lung cancer) benefit most from lung cancer screening. Thus, the effectiveness of computed tomography (CT) screening can be improved by focusing on high-risk populations. This review article summarizes the risk stratification models of the large European and American screening studies and discusses possible future biomarkers for risk stratification.

References

Gesthalter Y, Vick J, Steiling K, Spira A . Translating the transcriptome into tools for the early detection and prevention of lung cancer. Thorax. 2015; 70(5):476-81. DOI: 10.1136/thoraxjnl-2014-206605. View

Cronin K, Gail M, Zou Z, Bach P, Virtamo J, Albanes D . Validation of a model of lung cancer risk prediction among smokers. J Natl Cancer Inst. 2006; 98(9):637-40. DOI: 10.1093/jnci/djj163. View

Field J, Duffy S, Baldwin D, Whynes D, Devaraj A, Brain K . UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax. 2015; 71(2):161-70. PMC: 4752629. DOI: 10.1136/thoraxjnl-2015-207140. View

de Torres J, Bastarrika G, Wisnivesky J, Alcaide A, Campo A, Seijo L . Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest. 2007; 132(6):1932-8. DOI: 10.1378/chest.07-1490. View

Spitz M, Hong W, Amos C, Wu X, Schabath M, Dong Q . A risk model for prediction of lung cancer. J Natl Cancer Inst. 2007; 99(9):715-26. DOI: 10.1093/jnci/djk153. View

Kovalchik S, Tammemagi M, Berg C, Caporaso N, Riley T, Korch M . Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013; 369(3):245-254. PMC: 3783654. DOI: 10.1056/NEJMoa1301851. View

Park S, Cho L, Yang J, Park B, Chang S, Lee K . Lung cancer risk and cigarette smoking, lung tuberculosis according to histologic type and gender in a population based case-control study. Lung Cancer. 2009; 68(1):20-6. DOI: 10.1016/j.lungcan.2009.05.017. View

Li K, Husing A, Sookthai D, Bergmann M, Boeing H, Becker N . Selecting High-Risk Individuals for Lung Cancer Screening: A Prospective Evaluation of Existing Risk Models and Eligibility Criteria in the German EPIC Cohort. Cancer Prev Res (Phila). 2015; 8(9):777-85. DOI: 10.1158/1940-6207.CAPR-14-0424. View

Pegna A, Picozzi G, Mascalchi M, Carozzi F, Carrozzi L, Comin C . Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. Lung Cancer. 2008; 64(1):34-40. DOI: 10.1016/j.lungcan.2008.07.003. View

10.

Tammemagi M, Church T, Hocking W, Silvestri G, Kvale P, Riley T . Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med. 2014; 11(12):e1001764. PMC: 4251899. DOI: 10.1371/journal.pmed.1001764. View

11.

McCarthy W, Meza R, Jeon J, Moolgavkar S . Chapter 6: Lung cancer in never smokers: epidemiology and risk prediction models. Risk Anal. 2012; 32 Suppl 1:S69-84. PMC: 3485693. DOI: 10.1111/j.1539-6924.2012.01768.x. View

12.

Tammemagi M, Katki H, Hocking W, Church T, Caporaso N, Kvale P . Selection criteria for lung-cancer screening. N Engl J Med. 2013; 368(8):728-36. PMC: 3929969. DOI: 10.1056/NEJMoa1211776. View

13.

Becker N, Motsch E, Gross M, Eigentopf A, Heussel C, Dienemann H . Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening round. J Cancer Res Clin Oncol. 2012; 138(9):1475-86. DOI: 10.1007/s00432-012-1228-9. View

14.

Pastorino U, Rossi M, Rosato V, Marchiano A, Sverzellati N, Morosi C . Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012; 21(3):308-15. DOI: 10.1097/CEJ.0b013e328351e1b6. View

15.

Cassidy A, Myles J, van Tongeren M, Page R, Liloglou T, Duffy S . The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2007; 98(2):270-6. PMC: 2361453. DOI: 10.1038/sj.bjc.6604158. View

16.

Raji O, Duffy S, Agbaje O, Baker S, Christiani D, Cassidy A . Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. Ann Intern Med. 2012; 157(4):242-50. PMC: 3723683. DOI: 10.7326/0003-4819-157-4-201208210-00004. View

17.

Molina J, Yang P, Cassivi S, Schild S, Adjei A . Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008; 83(5):584-94. PMC: 2718421. DOI: 10.4065/83.5.584. View

18.

Zhang X, Sebastiani P, Liu G, Schembri F, Zhang X, Dumas Y . Similarities and differences between smoking-related gene expression in nasal and bronchial epithelium. Physiol Genomics. 2009; 41(1):1-8. PMC: 2841495. DOI: 10.1152/physiolgenomics.00167.2009. View

19.

Pedersen J, Ashraf H, Dirksen A, Bach K, Hansen H, Toennesen P . The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round. J Thorac Oncol. 2009; 4(5):608-14. DOI: 10.1097/JTO.0b013e3181a0d98f. View

20.

Hassanein M, Callison J, Callaway-Lane C, Aldrich M, Grogan E, Massion P . The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res (Phila). 2012; 5(8):992-1006. PMC: 3723112. DOI: 10.1158/1940-6207.CAPR-11-0441. View